Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R0FO
|
||||
| Former ID |
DCL000786
|
||||
| Drug Name |
E 7080
|
||||
| Synonyms |
E7080; E-7080, E7080; 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Ovarian cancer [ICD9: 183; ICD10:C56] | Phase 1 | [536839] | ||
| Company |
Eisai Co. Ltd.
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H19ClN4O4
|
||||
| Canonical SMILES |
COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC<br />4)Cl
|
||||
| InChI |
1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
|
||||
| InChIKey |
WOSKHXYHFSIKNG-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 204460-24-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14782907, 24126764, 44859775, 74753053, 99436922, 123098996, 123110209, 124757043, 125163847, 125749042, 126665901, 131314303, 131480711, 134221774, 135262444, 135626656, 135685148, 135685149, 135685168, 136367339, 136367958, 137262627, 137276042, 139802275, 144115929, 152258284, 152344144, 160647123, 162011787, 162037768, 162527769, 164041901, 174560999, 178103998, 180386840, 198978519, 202553041, 223669921, 223705252, 223913134, 227134592, 242060265, 247802696, 251911433, 251971223, 252150297, 252215326, 252215327, 252451828, 252543308
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [536839] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.